替吉奥和吉西他滨分别联合顺铂一线治疗EGFR野生型的晚期非小细胞肺癌的临床观察

被引:25
作者
孙成晖 [1 ]
吴国强 [1 ]
严伟红 [1 ]
孙钦文 [1 ]
柳宝 [2 ]
机构
[1] 阳春市人民医院肿瘤科
[2] 哈尔滨医科大学附属肿瘤医院
关键词
替吉奥; 晚期非小细胞肺癌; 表皮生长因子受体; 化疗;
D O I
10.13286/j.cnki.chinhosppharmacyj.2015.23.15
中图分类号
R734.2 [肺肿瘤];
学科分类号
100117 [系统生物医学];
摘要
目的:比较替吉奥联合顺铂方案和吉西他滨联合顺铂方案一线治疗表皮生长因子受体(EGFR)基因野生型的晚期非小细胞肺癌的疗效和安全性。方法:选取2010年7月-2011年12月收治的68例符合入组标准的EGFR基因野生型的晚期非小细胞肺癌患者,将其随机分为2组,观察组采用替吉奥联合顺铂方案进行一线化疗;对照组采用吉西他滨联合顺铂方案进行一线化疗。比较2组患者的近期疗效、无进展生存期和不良反应。结果:替吉奥联合顺铂组(观察组)和吉西他滨联合顺铂组(对照组)的总有效率分别为41.2%和38.2%,差异无统计学意义(P>0.05);中位无进展生存期分别为5.4个月和5.1个月,差异无统计学意义(P=0.088);不良反应中替吉奥组的血小板降低发生率(11.8%)低于吉西他滨组,差异有统计学意义(P<0.05)。结论:替吉奥联合顺铂方案一线治疗EGFR基因野生型的晚期非小细胞肺癌具有较好疗效,且不良反应较轻。
引用
收藏
页码:2129 / 2132
页数:4
相关论文
共 10 条
[1]
EGFR基因状态与晚期非小细胞肺癌患者一线化疗疗效的关系 [J].
秦娜 ;
张权 ;
王敬慧 ;
张卉 ;
顾艳斐 ;
杨新杰 ;
李曦 ;
吕嘉林 ;
吴羽华 ;
农靖颖 ;
张新勇 ;
张树才 .
中国肺癌杂志, 2015, (03) :131-137
[2]
晚期肺腺癌EGFR突变状态对培美曲塞疗效的影响 [J].
张琼 ;
杨哲 ;
戴洪海 ;
王瑜 ;
韩俊庆 .
中国肿瘤临床, 2013, 40 (22) :1378-1381
[3]
替吉奥化疗应用于中晚期肺癌的近期疗效和安全性评估 [J].
阎飞 ;
李兴华 .
中国肿瘤临床与康复, 2013, 20 (04) :359-361
[4]
EGFR突变状态对Ⅲ期非鳞非小细胞肺癌患者放化疗近期疗效和长期生存的预测价值 [J].
李付海 ;
白桦 ;
李夏南 ;
吴梅娜 ;
余荣 ;
石安辉 ;
尹丽 ;
王洁 ;
朱广迎 .
中国肺癌杂志, 2011, (09) :715-718
[5]
Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group [J].
Kentepozidis, N. ;
Kotsakis, A. ;
Soultati, A. ;
Agelaki, S. ;
Christophylakis, Ch. ;
Agelidou, M. ;
Chelis, L. ;
Papakotoulas, P. ;
Vamvakas, L. ;
Zafiriou, Z. ;
Samonis, G. ;
Georgoulias, V. .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (03) :605-612
[6]
Bevacizumab Maintenance in Patients with Advanced Non–Small-Cell Lung Cancer; Clinical Patterns; and Outcomes in the Eastern Cooperative Oncology Group 4599 Study: Results of An Exploratory Analysis.[J].Ariel Lopez-Chavez;Todd Young;Sophie Fages;Larry Leon;Joan H. Schiller;Afshin Dowlati;Julie R. Brahmer;David H. Johnson;Alan Sandler.Journal of Thoracic Oncology.2012, 11
[7]
Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer [J].
Stevenson, James P. ;
Langer, Corey J. ;
Somer, Robert A. ;
Evans, Tracey L. ;
Rajagopalan, Kumar ;
Krieger, Kimberly ;
Jacobs-Small, Mona ;
Dyanick, Nikolas ;
Milcarek, Barry ;
Coakley, Susan ;
Walker, Suzanne ;
Eaby-Sandy, Beth ;
Hageboutros, Alexandre .
CANCER, 2012, 118 (22) :5580-5587
[8]
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial [J].
Rosell, Rafael ;
Carcereny, Enric ;
Gervais, Radj ;
Vergnenegre, Alain ;
Massuti, Bartomeu ;
Felip, Enriqueta ;
Palmero, Ramon ;
Garcia-Gomez, Ramon ;
Pallares, Cinta ;
Miguel Sanchez, Jose ;
Porta, Rut ;
Cobo, Manuel ;
Garrido, Pilar ;
Longo, Flavia ;
Moran, Teresa ;
Insa, Amelia ;
De Marinis, Filippo ;
Corre, Romain ;
Bover, Isabel ;
Illiano, Alfonso ;
Dansin, Eric ;
de Castro, Javier ;
Milella, Michele ;
Reguart, Noemi ;
Altavilla, Giuseppe ;
Jimenez, Ulpiano ;
Provencio, Mariano ;
Angel Moreno, Miguel ;
Terrasa, Josefa ;
Munoz-Langa, Jose ;
Valdivia, Javier ;
Isla, Dolores ;
Domine, Manuel ;
Molinier, Olivier ;
Mazieres, Julien ;
Baize, Nathalie ;
Garcia-Campelo, Rosario ;
Robinet, Gilles ;
Rodriguez-Abreu, Delvys ;
Lopez-Vivanco, Guillermo ;
Gebbia, Vittorio ;
Ferrera-Delgado, Lioba ;
Bombaron, Pierre ;
Bernabe, Reyes ;
Bearz, Alessandra ;
Artal, Angel ;
Cortesi, Enrico ;
Rolfo, Christian ;
Sanchez-Ronco, Maria ;
Drozdowskyj, Ana .
LANCET ONCOLOGY, 2012, 13 (03) :239-246
[9]
BRIDGE: An Open-Label Phase II Trial Evaluating the Safety of Bevacizumab + Carboplatin/Paclitaxel as First-Line Treatment for Patients with Advanced; Previously Untreated; Squamous Non-small Cell Lung Cancer.[J].John D. Hainsworth;Liang Fang;Jane E. Huang;David Karlin;Kenneth Russell;Leonardo Faoro;Christopher Azzoli.Journal of Thoracic Oncology.2011, 1
[10]
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 [J].
Ferlay, Jacques ;
Shin, Hai-Rim ;
Bray, Freddie ;
Forman, David ;
Mathers, Colin ;
Parkin, Donald Maxwell .
INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (12) :2893-2917